The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Open accessAbstract
Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IFN γ and TNF α are key effector cytokines that contribute to anti-tumour immune responses 9,11,27-30 , and genes associated with IFN and TNF signaling pathways contribute to immune evasion 4,9,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Chronic IFN signaling can also promote an immune suppressive environment126.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [126]
In the citing paper
“The expression of PD-L1 and MHC II, which may cause exhaustion by binding to T-cell programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3), respectively, is regulated by tumor interferon (IFN) signaling.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“In solid tumors, a tumor IFN–stimulated gene signature termed ISG.RS is associated with a multigenic program of T-cell exhaustion and worse outcomes after immune checkpoint blockade.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“One part of this program is to increase tumor expression of multiple T-cell ligands that lead to exhaustion of T cells infiltrating the TME.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“When tumors express a gene signature (ISG.RS) consisting of genes coordinately activated by multiple types of IFN, a multigenic therapy resistance program is activated.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“Recently, the Minn group elucidated how chronic IFN signaling mediates immunosuppression and resistance to radiation and immune checkpoint inhibitor therapy in solid tumors.2,24,54”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“interferon signaling is of central importance to antitumor immune response43.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 801–900 of 1,000
Meng, Y., Zhou, L., Xia, Y., Jia, C., & Huang, L. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118703 · Cited by 12
Persistent IFN-γ signaling in acquired resistance to PD-(L)1 blockade in NSCLC
Karri, V., & Dalia, S. M. (2025) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2025.90 · Cited by 8
Mucosal Melanoma: Mechanisms of Its Etiology, Progression, Resistance and Therapy
Hassan, S.-Y., Flanagan, T. W., Hassan, S.-L., Facca, S., Haïkel, Y., & Hassan, M. (2025) · Cells · doi:10.3390/cells14231884 · Cited by 7
Sauerer, T., Lischer, C., Weich, A., Berking, C., Vera, J., & Dörrie, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.785662 · Cited by 7
Tumor immune evasion: insights from CRISPR screens and future directions
Djajawi, T. M., Wichmann, J., Vervoort, S. J., & Kearney, C. J. (2023) · FEBS Journal · doi:10.1111/febs.17003 · Cited by 7
Resistance Management for Cancer: Lessons from Farmers
Seyedi, S., Harris, V. K., Kapsetaki, S. E., Narayanan, S., Saha, D. K., Compton, Z. T., Yousefi, R., May, A., Fakir, E., Boddy, A. M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3374 · Cited by 8
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer
Flynn, M., Young, K., Cunningham, D., & Starling, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786228 · Cited by 7
Zhang, Q., Liu, S., Liu, Y., Bhatt, D. M., Estrada, J., Belmontes, B., Ren, X., Canon, J. R., & Ouyang, W. (2022) · Advanced Genetics · doi:10.1002/ggn2.202200002 · Cited by 6
Barba, C., Ekiz, H. A., Tang, W. W., Ghazaryan, A., Hansen, M., Lee, S.-H., Voth, W. P., & O’Connell, R. M. (2023) · Cancers · doi:10.3390/cancers15051411 · Cited by 8
Better VISTAs ahead? Potential and pitfalls of immunotherapy
Madan, R. A., & Gulley, J. L. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.75 · Cited by 7
Li, X., Zeng, S., He, H., Zeng, X., Peng, L., & Chen, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s259516 · Cited by 7
Mathew, D., Marmarelis, M. E., Foley, C., Bauml, J. M., Ye, D., Ghinnagow, R., Ngiow, S. F., Klapholz, M., Jun, S., Zhang, Z., et al. (2022) · medRxiv · doi:10.1101/2022.11.05.22281973 · Cited by 7
Self-citationChronic interferon-stimulated gene transcription promotes oncogene-induced breast cancerPreprint
Wang, H., Canasto‐Chibuque, C., Kim, J. H., Hohl, M., Leslie, C. S., Reis-Filho, J. S., & Petrini, J. H. J. (2024) · Genes & Development · doi:10.1101/gad.351455.123 · Cited by 7
Inhibition of anti-tumor immunity by melanoma cell-derived Activin-A depends on STING
Pinjušić, K., Ambrosini, G., Lourenço, J., Fournier, N., Iseli, C., Guex, N., Egorova, O., Nassiri, S., & Constam, D. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1335207 · Cited by 6
Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Shi, Y., McKenery, A., Dolan, M., Mastri, M., Hill, J. W., Dommer, A. P., Benzekry, S., Long, M., Abrams, S. I., Puzanov, I. J., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00333-0 · Cited by 8
Clinical Utility of IFIT Proteins in Human Malignancies
Parsyan, A. E., Kochiyanil, A., Bonvissuto, A. C., Bhat, V., & Allan, A. L. (2025) · Biomedicines · doi:10.3390/biomedicines13061435 · Cited by 6
Wu, M., Yang, S., Yang, Z., Fan, J., Lomeli, S. H., Dharanipragada, P., Moriceau, G., Damoiseaux, R. D., Kelley, M. C., Granada, C. N. P., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.001 · Cited by 6
Shi, Y., Feng, D., Zhou, J., Liu, L., Li, X., Yuan, Z., Wu, J., & Yao, H. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.010 · Cited by 8
In vivo detection of immune responses via cytokine activity labeling
Lu, G., Zhang, S., Feng, M., Kim, E., Cho, D., Kim, J. H., Caris, H., Silberstein, L., Choi, G. B., & Huh, J. R. (2026) · Cell · doi:10.1016/j.cell.2025.12.011 · Cited by 6
Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy
Žák, J., & Teijaro, J. R. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01266-6 · Cited by 6
Langbein, L. E., Hajjar, R. E., Kim, W. Y., & Yang, H. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00255.2022 · Cited by 8
Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy
Johnson, G. A., & Locke, F. L. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.07.003 · Cited by 6
Chen, H., He, J., Wang, L., Lin, Y., Mou, Z., Huang, X., & Chen, L. (2023) · Lupus · doi:10.1177/09612033231204765 · Cited by 6
Zhou, Y., Qin, X. Y., Hu, Q., Qin, S., Xu, R., Gu, K., & Lu, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-52128-x · Cited by 6
Ko, K.-P., Zhang, S., Huang, Y., Kim, B.-J., Zou, G., Jun, S., Zhang, J., Zhao, Y., Martin, C., Dunbar, K. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109795 · Cited by 6
Immunotherapy‐induced reprogramming of cancer‐associated fibroblasts can promote tumor progression
Yamashita, T., Horiguchi, H., Kadomatsu, T., Sato, M., Moroishi, T., & Oike, Y. (2024) · Genes to Cells · doi:10.1111/gtc.13177 · Cited by 6
Immunomodulatory antitumor effect of interferon‑beta combined with gemcitabine in pancreatic cancer
Blaauboer, A., van Koetsveld, P. M., Mustafa, D. A. M., Dumas, J., Dogan, F., van Zwienen, S., van Eijck, C. H. J., & Hofland, L. J. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5387 · Cited by 6
Construction of a solid Cox model for AML patients based on multiomics bioinformatic analysis
Fu, L., Cai, J., Liu, J., Yu, S., Zhang, X., Su, Y. R., & Gao, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925615 · Cited by 6
Investigating Mammalian Formins with SMIFH2 Fifteen Years in: Novel Targets and Unexpected Biology
Innocenti, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109058 · Cited by 7
Ma, Z., Liang, H., Cui, R., Ji, J., Liu, H., Liu, X., Shen, P., Wang, H., Wang, X., Song, Z., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01173-9 · Cited by 6
Shpilman, Z., & Kidane, D. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241248330 · Cited by 6
The therapeutic impact of programmed death – 1 in the treatment of colorectal cancer
Sangani, P. S., Yazdani, S., Khalili‐Tanha, G., Ghorbani, E., Al-Hayawi, I. S., Fiuji, H., Khazaei, M., Hassanian, S. M., Kiani, M. A., Ghayour‐Mobarhan, M., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155345 · Cited by 6
Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas
Gross, E. T. E., Peinado, C. D., Jung, Y., Han, S., Liu, B., Santosa, E. K., & Bui, J. D. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1404212 · Cited by 6
Chen, X., Zeng, F., & Zhang, Y. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13023 · Cited by 6
Hamm, C. A., Pry, K. J., Lu, J. Z., & Bacus, S. S. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.04.004 · Cited by 6
Kim, Y., Gil, J., Plá, I., Sánchez, A., Betancourt, L. H., Lee, B., Appelqvist, R., Ingvar, C., Lundgren, L., Olsson, H. L., et al. (2020) · Cancers · doi:10.3390/cancers12030767 · Cited by 6
Pourmir, I., Gazeau, B., Basile, H. D. S., & Fabre, E. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.14 · Cited by 5
Sinha, D., Smith, C., & Khanna, R. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.005 · Cited by 6
Zalba, S., Belsúe, V., Topp, B. G., de Alwis, D. P., Álvarez, M., Trocóniz, I. F., Berraondo, P., & Garrido, M. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01239-z · Cited by 6
Choong, W.-K., & Sung, T. (2021) · iScience · doi:10.1016/j.isci.2021.102522 · Cited by 6
Wu, G., Yang, Y., Zhu, Y., Li, Y., Zhai, Z., An, L., Liu, M., Zheng, Y., Wang, Y., Zhou, Y., et al. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.742443 · Cited by 6
Kasichayanula, S., Mandlekar, S., Shivva, V., Patel, M. R., & Girish, S. (2022) · Clinical and Translational Science · doi:10.1111/cts.13312 · Cited by 6
TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy
Kelliher, M. A., & Fitzgerald, K. A. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.01.009 · Cited by 6
Memon, D., Rizvi, H. A., Fromm, G. J., Lihm, J., Schoenfeld, A. J., Sauter, J. L., Luo, J., Chow, A. T., Bhanot, U. K., McCarthy, C. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.21.452854 · Cited by 6
Self-citationMelanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanismsPreprint
Gruen, C., Yang, H. H., Sassano, A., Wu, E., Gopalan, V., Marie, K. L., Castro, A., Mehrabadi, F. R., Wu, C. H., Church, I., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.03.535074 · Cited by 5
Jin, R., Du, F., Han, X., Guo, J., Song, W., Xia, Y., Yue, X., Yang, D., Tong, J., Zhang, Q., et al. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-05006-1 · Cited by 5
Ou, H., Huang, H., Xu, Y., Lin, H., & Wang, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107662 · Cited by 7
Chen, H., Wang, Z., Sun, C., Zhong, Y., Liu, Y., Li, Y., Zhang, T., Zhang, Y., Zhu, X., Li, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202501333 · Cited by 5
A-to-I RNA editing in hematologic immunity and malignancy
Gan, W. L., & Chen, L. (2025) · Experimental Hematology · doi:10.1016/j.exphem.2025.104861 · Cited by 5
Repeats mimic pathogen-associated patterns across a vast evolutionary landscape
Šulc, P., Gioacchino, A. D., Solovyov, A., Sun, S., Martis, S., Marhon, S. A., Lindholm, H. T., Chen, R., Hosseini, A., Jiang, H. L., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.101011 · Cited by 21
Gupta, R., Radhakrishnan, R. A., Kabekkodu, S. P., & Chakrabarty, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189504 · Cited by 5
CRISPR screens define unified hallmarks of cancer cell-autonomous immune evasion
Huber, A., Djajawi, T. M., Rivera, S., Vervoort, S. J., & Kearney, C. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116738 · Cited by 5
Khorramdelazad, H., Arfaei, R., Yaraghi, P., Boroumand, A., Kheyri, A., Shirzad, Z., Kheiri, F., & Bagheri, V. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105218 · Cited by 5
Zhou, L., Liu, Q., He, Y., Tang, Y., Liu, S., Wang, X., Shen, S., Ji, J., Liu, Z., Zeng, X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1737661 · Cited by 7
Regulation of immune checkpoint molecules in cancer immune evasion and therapy
Eris, C., Zu, C., Xiao, Y., Platten, M., & Sun, C. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00934-y · Cited by 7
IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics
Ming, Z., Lim, S. Y., Stewart, A., Pedersen, B., Shklovskaya, E., Menzies, A. M., Carlino, M. S., Kefford, R. F., Lee, J., Scolyer, R. A., et al. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.01.017 · Cited by 5
Zahavi, D. J., Erbe, R., Zhang, Y., Guo, T. W., Malchiodi, Z. X., Maynard, R. E., Lekan, A. A., Gallagher, R. I., Wulfkuhle, J. D., Petricoin, E. F., et al. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2269637 · Cited by 6
Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors
Hackett, J. B., Ramos, N., Barr, S. M., Bross, M., Viola, N. T., & Gibson, H. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1285117 · Cited by 5
Nakashoji, A., Haratake, N., Bhattacharya, A., Mao, W., Xu, K., Wang, K., Daimon, T., Ozawa, H., Shigeta, K., Fushimi, A., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0011 · Cited by 5
Fan, T., Xiao, C., Deng, Z., Li, S., Tian, H., Zheng, Y., Zheng, B. J., Li, C., & He, J. Y. (2025) · Respiratory Research · doi:10.1186/s12931-024-03093-6 · Cited by 5
Interleukin-4 modulates type I interferon to augment antitumor immunity
Newnes, H. V., Armitage, J. D., Buzzai, A. C., de Jong, E., Audsley, K. M., Barnes, S. A., Srinivasan, S., Serralha, M., Fear, V. S., Guo, B. B., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt3618 · Cited by 5
Lac water extract inhibits IFN-γ signaling through JAK2-STAT1-IRF1 axis in human melanoma
Li, L., Yokoyama, S., Han, N., & Hayakawa, Y. (2018) · RSC Advances · doi:10.1039/c8ra02955e · Cited by 5
Blangero, F., Robert, M., Andraud, T., Dumontet, C., Vidal, H., & Eljaafari, A. (2023) · Cancers · doi:10.3390/cancers15112963 · Cited by 5
The Expression Characteristics and Function of the RECQ Family in Pan-Cancer
Zhou, Y., Huang, X., Wang, L., & Luo, Y. (2023) · Biomedicines · doi:10.3390/biomedicines11082318 · Cited by 5
Yu, J., An, N., Zhu, J., Zhu, B., Zhang, G., Chen, K., Zhou, Y., Ye, T., & Li, G. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200878 · Cited by 5
Sequential JAK inhibition enhances antitumor immunity after combined anti–PD-1 and anti-CTLA4
Arias-Badia, M., Chen, P., Lwin, Y. M., Srinath, A., Lyu, A., Fan, Z., Kwek, S. S., Luong, D., Setayesh, A., Sakamoto, M., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187921 · Cited by 7
Cerqueira, O. L. D., Antunes, F., de Assis, N. G., Cardoso, E. C., Clavijo-Salomon, M. A., Domingues, A. C. M., Tessarollo, N. G., & Strauss, B. E. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.777775 · Cited by 5
Röhl, L., Wellhausen, J., Berszin, M., Krücken, I., Zebralla, V., Pirlich, M., Wiegand, S., Dietz, A., Wald, T., & Wichmann, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237623 · Cited by 5
Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
Shibata, Y., Kishida, T., Kouro, T., Wei, F., Igarashi, Y., Himuro, H., Noguchi, T., Koizumi, M., Suzuki, T., Osaka, K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1269935 · Cited by 5
Visan, I. (2017) · Nature Immunology · doi:10.1038/ni.3670 · Cited by 5
Reva, B. A., Omelchenko, T., Calinawan, A. P., Nair, S. S., Schadt, E. E., & Tewari, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.19.345629 · Cited by 5
A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunityPreprint
Liang, S., Tran, E., Du, X., Dong, J., Sudholz, H., Chen, H., Qu, Z., Huntington, N. D., Babon, J. J., Kershaw, N. J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.16.545220 · Cited by 5
Qiu, J., Ye, D., Chen, X. E., Dangle, N. J., Yoshor, B., Zhang, T., Shao, Y., Nallamala, V. C., Wang, S., Ren, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.13.607862 · Cited by 5
Self-citationWinterhoff, B. J. N., Girnius, N., Liu, M., Kang, J., Shetty, M., Martinez-Gakidis, M. A., Xu, W., Thomas, M., Lahmadi, L., Henstridge, A. Z., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.24.661404 · Cited by 5
Poddar, S., Yan, J., Tiwari, G., Rinchai, D., Budka, J. A., Zhang, W., Peng, W., Salunkhe, S., Davis, M. J., Song, Q., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181893 · Cited by 4
Takamori, S., Haratake, N., Bhattacharya, A., Kikutake, C., Ozawa, H., Shigeta, K., Nakashoji, A., Isozaki, H., Shimokawa, M., Suyama, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02482-7 · Cited by 4
Lee, H.-J., Cho, E., Song, K., & Kim, T. W. (2026) · Immune Network · doi:10.4110/in.2026.26.e11 · Cited by 4
Liquid-liquid phase separation in cancer therapy resistance
Hu, P., Ding, H., Yue, N., Ye, J., Ruan, S., Qian, Y., Wang, C., & Song, D. (2026) · iScience · doi:10.1016/j.isci.2026.115420 · Cited by 4
Zhao, Y., Shang, Y., Luan, T., Yu, Z., Yang, Y., Niu, X., Li, H., Wang, S., Wang, C., & Liu, L. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02674-x · Cited by 4
Fiorilla, I., Ghezzi, B., Ponzano, A., Moiso, E., Riccardo, F., Tommasi, N., Avalle, L., Carrà, G., Ugolini, F., Calussi, E., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03734-2 · Cited by 4
Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial
Gentner, B., Eoli, M., Francesca, F., Barcella, M., Capotondo, A., Mazzoleni, S., Brambilla, V., Francavilla, A., Garramone, M., Carrabba, M. G., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04419-1 · Cited by 4
Zhou, Y., Rao, W., Zhao, L., Guo, W., Shao, F., Zhang, Z., Zhang, H., Liu, T., Li, Z., Tan, F., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-391 · Cited by 4
JUN–ENPP1–cGAS–STING axis mediates immune evasion and tumor progression in bladder cancer
You, C., Fang, Q., Qing, L., Xiao, X., Liu, Y., Yang, W., Li, Q., Li, R., Wang, Y., & Dong, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07275-8 · Cited by 4
Liu, C.-A., Harn, H., Chen, K.-P., Lee, J.-H., Lin, S., & Chiu, T. (2022) · Journal of Oncology · doi:10.1155/2022/3236058 · Cited by 4
The systemic effect of type 1 interferon responsiveness on tumor immunotherapy
Su, S., & Song, E. (2022) · Nature Immunology · doi:10.1038/s41590-022-01275-2 · Cited by 4
Wu, C., Casanova, R., Mairinger, F. D., & Soltermann, A. (2022) · Frontiers in Oncology · doi:10.2139/ssrn.4133126 · Cited by 4
Shao, L., Srivastava, R., Delgoffe, G. M., Thorne, S. H., & Sarkar, S. N. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0573 · Cited by 4
A myeloid IFN gamma response gene signature correlates with cancer prognosis
Zhang, Y., Khanniche, A., Li, Y., Wu, Z., Wang, H., Zhang, H., Li, X., Hu, L., & Kong, X. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70139 · Cited by 4
Cui, B., Cao, X., Zou, W., Wan, Y., Wang, N., Wang, Y., Li, P., Hua, F., Liu, Y., Zhang, X., et al. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.06.007 · Cited by 4
Zhou, Z., Zheng, Y., Mo, S., Li, S., Zheng, X., Wei, R., Fan, T. T., Chen, T., Xiao, C., Li, C., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.71385 · Cited by 4
GSTA4 Governs Melanoma Immune Resistance and Metastasis
Ucche, S., Yokoyama, S., Mojić, M., Oki, K., Ohshima, C., Tsuihiji, H., Takasaki, I., Tahara, H., & Hayakawa, Y. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0369 · Cited by 4
Lara-Vega, I., Maximiliano, C. L., & López, A. V. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.05.002 · Cited by 4
Magrone, T., & Jirillo, E. (2019) · Current Pharmaceutical Design · doi:10.2174/138161282445190416154917 · Cited by 4
Radio-Immunology of Ablative Radiation
Savage, T., & Guha, C. (2019) · Springer eBooks · doi:10.1007/978-3-030-16924-4_2 · Cited by 4
Saman, H. T., Saman, H. T., Shahab Uddin, M. S., Raza, S. S., Shrimali, R. K., & Rasul, K. I. (2020) · Clinical Oncology and Research · doi:10.31487/j.cor.2020.09.08 · Cited by 3
Pinto-Fernández, A., Salio, M., Partridge, T., Chen, J., Vere, G., Greenwood, H., Olie, C. S., Damianou, A., Scott, H. C., Pegg, H. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.31.005629 · Cited by 4
Trials and Tribulations of Radio-Immuno-Oncology
Guha, C. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.01.001 · Cited by 4
Multicellular immune hubs and their organization in MMRd and MMRp colorectal cancerPreprint
Pelka, K., Hofree, M., Chen, J. H., Sarkizova, S., Pirl, J. D., Jorgji, V., Bejnood, A., Dionne, D. A., Ge, W. H., Xu, K. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.30.426796 · Cited by 4
Dhainaut, M., Rose, S. A., Aktürk, G., Wroblewska, A., Park, E. S., Nielsen, S. R., Buckup, M., Roudko, V., Pia, L., Bérichel, J. L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.13.451021 · Cited by 4
Berzofsky, J. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732660162.793559544 · Cited by 4
Metadata
- Authors
- Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., Gangadhar, T. C., Amaravadi, R. K., Schuchter, L. M., Feldman, M. D., Ishwaran, H., Vonderheide, R. H., Maity, A., Wherry, E. J., & Minn, A. J.
- Affiliations
- University of Pennsylvania (US)
- University of Miami (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Minn, Andy J.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 167
- Issue
- 6
- Pages
- 1540-1554.e12
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5385895
- OpenAlex
- W2558219863
- Cited by
- 1,216
- References
- 42
- Citations by year
- 2026: 150 · 2025: 124 · 2024: 127 · 2023: 135 · 2022: 128 · 2021: 140 · 2020: 140 · 2019: 114 · 2018: 92 · 2017: 64 · 2016: 1
- FWCI
- 48.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo
- Funders
- Melanoma Research Alliance
- Parker Institute for Cancer Immunotherapy
- Robertson Foundation
- Cancer Research Institute Irvington Fellowship
- NIH (P50CA174523, R01CA163739, R01CA158186, P30CA016520, U19AI082630, R01AI105343, U01AI095608, P01AI112521)
- Basser Research Center for BRCA
- Abramson Cancer Center Translational Center of Excellence in Pancreatic Cancer
- Department of Defense Era of Hope Scholar (W81XWH-09-1-0339)
- NCI (R01CA172651)
- Merck
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitor resistance, type I interferon, interferon-gamma, PD-1 pathway, PD-L1, STAT1, interferon-stimulated genes, T cell inhibitory receptors, T cell exhaustion, radiotherapy, tumor immune microenvironment, resistance biomarkers, anti-PD-1 therapy
- MeSH terms
- Animals, Humans, Interferons, Melanoma, Neoplasm Transplantation, T-Lymphocytes, Radioimmunotherapy, Drug Resistance, Neoplasm, Cell Line, Tumor, STAT1 Transcription Factor, Mice, B7-H1 Antigen, CTLA-4 Antigen, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
